Analysis of risk characteristics for metachronous metastasis in different period of nasopharyngeal carcinoma

BMC Cancer

Table 2 Baseline characteristics and chi-square test for NMM, EMM and LMM group

Characteristic	NMM group (n = 3920)		EMM group (n = 346)		NMM VS. EMM	LMM group (n = 168)		NMM VS. LMM
Sex					0.009			0.079
Female	1107	28.20%	75	21.70%		37	22.00%
Male	2813	71.80%	271	78.30%		131	78.00%
Age (year)					0.011			0.532
≤50	2332	59.50%	230	66.50%		104	61.90%
>50	1588	40.50%	116	33.50%		64	38.10%
T-stage					0.007			0.683
1	789	20.10%	54	15.60%		33	19.60%
2	812	20.70%	61	17.60%		29	17.30%
3	1330	33.90%	117	33.80%		59	35.10%
4	989	25.20%	114	32.90%		47	28.00%
N-stage					< 0.001			< 0.001
0	391	10.00%	10	2.90%		9	5.40%
1	1370	34.90%	57	16.50%		40	23.80%
2	1543	39.40%	160	46.20%		66	39.30%
3	616	15.70%	119	34.40%		53	31.50%
Pre-NLR					0.001			0.17
<2.045	1980	50.90%	143	41.40%		75	45.50%
≥2.045	1909	49.10%	202	58.60%		90	54.50%
Pre-HB (g/L)					0.059			0.012
≤143	1920	49.40%	152	44.10%		65	39.40%
>143	1970	50.60%	193	55.90%		100	60.60%
Pre-PLR					0.067			0.220
<125	1981	50.90%	158	45.80%		76	46.10%
≥125	1908	49.10%	187	54.20%		89	53.90%
Pre-EBV DNA (copy/ml)					0.002			0.873
0	1011	26.70%	62	19.00%		42	26.10%
>0	2782	73.30%	265	81.00%		119	73.90%
Post-HB (g/L)					0.147			0.213
<122	1838	47.10%	177	51.20%		70	42.20%
≥122	2065	52.90%	169	48.80%		96	57.80%
Post-EBV DNA (copy/ml)					< 0.001			0.181
0	3208	89.80%	226	73.90%		127	86.40%
>0	365	10.20%	80	26.10%		20	13.60%

Abbreviations: Pre-NLR neutrophil to lymphocyte ratio before treatment, Pre-HB hemoglobin before treatment, Pre-PLR platelet to lymphocyte ratio before treatment, Pre-EBV DNA Epstein-Barr virus DNA before treatment, Post-HB hemoglobin after chemoradiotherapy, Post-EBV DNA Epstein-Barr virus DNA after chemoradiotherapy, NMM non-metachronous metastasis, EMM early metachronous metastasis (metastasis within 2 years after treatment), LMM late metachronous metastasis (metastasis beyond 2 years after treatment)

ISSN: 1471-2407